Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2008-3-3
pubmed:abstractText
Cisplatin is one of the most effective anti-cancer drugs; however, the use of cisplatin is limited by its toxicity in normal tissues, particularly injury of the kidneys. The mechanisms underlying the therapeutic effects of cisplatin in cancers and side effects in normal tissues are largely unclear. Recent work has suggested a role for p53 in cisplatin-induced renal cell apoptosis and kidney injury; however, the signaling pathway leading to p53 activation and renal apoptosis is unknown. Here we demonstrate an early DNA damage response during cisplatin treatment of renal cells and tissues. Importantly, in the DNA damage response, we demonstrate a critical role for ATR, but not ATM (ataxia telangiectasia mutated) or DNA-PK (DNA-dependent protein kinase), in cisplatin-induced p53 activation and apoptosis. We show that ATR is specifically activated during cisplatin treatment and co-localizes with H2AX, forming nuclear foci at the site of DNA damage. Blockade of ATR with a dominant-negative mutant inhibits cisplatin-induced p53 activation and renal cell apoptosis. Consistently, cisplatin-induced p53 activation and apoptosis are suppressed in ATR-deficient fibroblasts. Downstream of ATR, both Chk1 and Chk2 are phosphorylated during cisplatin treatment in an ATR-dependent manner. Interestingly, following phosphorylation, Chk1 is degraded via the proteosomal pathway, whereas Chk2 is activated. Inhibition of Chk2 by a dominant-negative mutant or gene deficiency attenuates cisplatin-induced p53 activation and apoptosis. In vivo in C57BL/6 mice, ATR and Chk2 are activated in renal tissues following cisplatin treatment. Together, the results suggest an important role for the DNA damage response mediated by ATR-Chk2 in p53 activation and renal cell apoptosis during cisplatin nephrotoxicity.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/ATR protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Atr protein, mouse, http://linkedlifedata.com/resource/pubmed/chemical/Cell Cycle Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Checkpoint kinase 1, http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins, http://linkedlifedata.com/resource/pubmed/chemical/H2AFX protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Histones, http://linkedlifedata.com/resource/pubmed/chemical/Proteasome Endopeptidase Complex, http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Protein-Serine-Threonine Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Proteins, http://linkedlifedata.com/resource/pubmed/chemical/ataxia telangiectasia mutated..., http://linkedlifedata.com/resource/pubmed/chemical/checkpoint kinase 2
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0021-9258
pubmed:author
pubmed:issnType
Print
pubmed:day
7
pubmed:volume
283
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6572-83
pubmed:dateRevised
2011-11-2
pubmed:meshHeading
pubmed-meshheading:18162465-Animals, pubmed-meshheading:18162465-Antineoplastic Agents, pubmed-meshheading:18162465-Apoptosis, pubmed-meshheading:18162465-Cell Cycle Proteins, pubmed-meshheading:18162465-Cell Line, Transformed, pubmed-meshheading:18162465-Cisplatin, pubmed-meshheading:18162465-DNA Damage, pubmed-meshheading:18162465-DNA-Binding Proteins, pubmed-meshheading:18162465-Gene Deletion, pubmed-meshheading:18162465-Histones, pubmed-meshheading:18162465-Humans, pubmed-meshheading:18162465-Kidney Diseases, pubmed-meshheading:18162465-Kidney Tubules, Proximal, pubmed-meshheading:18162465-Neoplasms, pubmed-meshheading:18162465-Proteasome Endopeptidase Complex, pubmed-meshheading:18162465-Protein Kinases, pubmed-meshheading:18162465-Protein-Serine-Threonine Kinases, pubmed-meshheading:18162465-Rats, pubmed-meshheading:18162465-Signal Transduction, pubmed-meshheading:18162465-Tumor Suppressor Protein p53, pubmed-meshheading:18162465-Tumor Suppressor Proteins
pubmed:year
2008
pubmed:articleTitle
ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.
pubmed:affiliation
Department of Cellular Biology and Anatomy, Center for Biotechnology and Genomic Medicine, Medical College of Georgia and Charlie Norwood Veterans Affairs Medical Center, 1459 Laney Walker Boulevard, Augusta, GA 30912, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural